Preserving the intellectual output & resources of the University of Missouri.
Large trial finds adding an ARB to an ACE-I does not help diabetic nephropathy
MOspace/Manakin Repository
Breadcrumbs Navigation
Large trial finds adding an ARB to an ACE-I does not help diabetic nephropathy
Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/7447
| Title: | Large trial finds adding an ARB to an ACE-I does not help diabetic nephropathy |
| Author: | Stevermer, James J.; Misra, Shamita |
| Keywords: | combination therapy |
| Date: | 2009-04 |
| Publisher: | Family Physicians Inquiries Network |
| Citation: | Evidence Based Practice 12(4): 01-02. |
| Abstract: | While some evidence suggests that combining angiotensin converting-enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) might have clinically important benefits in some situations (particularly for patients with severe congestive heart failure [CHF]), a recent large randomized controlled trial (RCT) recently found no tangible benefit to combination therapy in patients with diabetes or arteriosclerotic cardiovascular disease without heart failure. |
| URI: | http://hdl.handle.net/10355/7447 |
Items in MOspace are protected by copyright, with all rights reserved, unless otherwise indicated.
This item appears in the following Collection(s)
-
Evidence Based Practice, 2009 (MU) [160]
The articles from the 2009 issues of Evidence Based Practice.